JetBlue Airways Corporation vs Nuwellis Inc — how do they compare? JetBlue Airways Corporation trades at $5.81 (market cap $2.13B), while Nuwellis Inc trades at $1.49 (market cap $522.76K). The key difference: JetBlue Airways Corporation is far larger — about 4074.5× Nuwellis Inc's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| JBLU | NUWE | |
|---|---|---|
Market Cap | $2.13B | $522.76K |
Sector | Industrials | Technology |
52-Week High | $6.46 | $220.50 |
52-Week Low | $4.03 | $1.42 |
Enterprise Value | $9.49B | -$1.29M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →